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ABSTRACT 
   We herein report the design and synthesis of benzothiazinones containing a piperidine moiety as new antitubercular 
agents based on the structure feature of IMB-ZR-1 discovered in our lab. Some of them were found to have good in 
vitro activity (MIC < 1 µg/mL) against drug-susceptible Mycobacterium tuberculosis H37RV strain. After two set of 
modifications, compound 2i were found to display comparable in vitro anti-TB activity (MIC < 0.016 µg/mL) to 
PBTZ169 against drug-sensitive and resistant mycobacterium tuberculosis strains. Compound 2i also showed 
acceptable PK profiles. Studies to determine PK profiles in lung and in vivo efficacy of 2i are currently under way.   
KEYWORDS:  benzothiazionones, PBTZ169, antimycobacterial activity, synthesis 
1. Introduction
   Tuberculosis (TB) is caused mainly by mycobacterium tuberculosis (MTB), has existed for millennia and 
remains a major global health problem.[1] The World Health Organization (WHO) estimated that approximately 10.4 
million people were infected and 1.3 million died from TB worldwide in 2016.[2] The current guidelines for treatment 
of drug-susceptible TB infection recommends a combination of four front-line drugs rifampin, isoniazid, pyrazinamide 
and ethambutol for 6-9 months, often leading to significant side effects and poor patient compliance. In addition, the 
spread of multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB has rendered these front-line drugs 
ineffective. [3] Therefore, there is an urgent need for discovery of new drugs with new mechanisms of action. Although 
Bedaquiline (inhibition of mitochondrial ATP synthase) and Delamanid (inhibition mycolic acid biosynthesis) were 
approved for the treatment of MDR-TB, over a huge gap of over 40 years, [4-5] both of them have pronounced issues, 
including hERG toxicity concerns, as well as multiple ADME issues due to their high lipophilicity. [6]  
Benzothiazinones (BTZs), a novel class of TB agents were reported to have strong inhibitory potency against 
drug-sensitive TB, MDR-TB and XDR-TB strains targeting on decaprenyl phosphoryl-β-D-ribose 2ʹ-epimerase 
(DprE1). [7-12] The most advanced compound from this series (PBTZ169, Figure 1), developed by the Swiss Federal 
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Graphic abstracts:  
 
 
    New benzothiazinones bearing a piperidine moiety were designed and synthesized as 
antitubercular agents based on the structure feature of IMB-ZR-1 discovered in our lab. 
Compound 2i were found to display potent anti-TB activity (MIC < 0.016 µg/mL) against 
drug-sensitive/resistant MTB strains.  
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Institute of Technology and Innovative Medicines, has progressed into Phase II clinical trials in Russian Federation for 
the treatment of both drug-susceptible TB and MDR-TB.[2] 
 
                          <INSERT FIGURE 1 HERE> 
 
The structure-activity relationship (SAR) and mechanistic studies of BTZs suggest that the NO2 group at position 
8 and the sulfur atom at position 1 are critical for activity, that the -CF3 at position 6 plays an important role in 
maintaining activity. [7, 13-20] In our previous study, we focused on the modification at position 2, some of the 
resulting compounds were found to have improved activity and pharmacokinetic properties. [11, 12] Among them, 
IMB-ZR-1 with the piperidine ring displayed potent in vitro anti-TB activity against the tested MDR-TB strains (MIC 
= 0.016 µg/mL). [12] Inspired by the above research results, we designed and synthesized two series of new BTZs 1-2 
with piperidine moiety as ring A (Figure 1.). Shorten the linker between the two cycles of IMB-ZR-1 by removing the 
methylene group gave the series 1; shifting the nitrogen atom in the linker to ring B provided the series 2. In order to 
explore SAR of these BTZs, the R group on series 1 could be methyl or hydrogen; the W moiety of series 2 could be 
piperidine, pyrrolidine, azepane, 4-methylpiperazine, diethylamino, or substituted piperidine, et al. The 
antimycobacterial activity of all the target compounds were evaluated against drug-susceptible TB strain. The potent 
compound 2i was further evaluated for antimycobacterial activity against MDR-TB strains, and in vivo PK properties, 
aiming to identify alternative group at position 2 of BTZs and find more effective DprE1 inhibitors as anti-TB 
candidates.  
                              <INSERT SCHEME 1 HERE> 
2. Results and Discussion 
2.1 Chemistry 
     Detailed synthetic pathways to target compounds 1a-b and 2a-k are outlined in scheme 1. Reductive amination 
of ketone 3 and N-methylcyclohexylamine or cyclohexylamine by NaCNBH3 in MeOH afforded compounds 4a-b. Boc 
deprotection by TFA in DCM gave the intermediates 5a-b. Coupling of 5a-b and 6 which was prepared according 
literature procedure [8] furnished the BTZs 1a-b. Condensation of the acid 7 with amines in the presence of EDC and 
HOBt yielded compounds 8a-k. Removal of the Boc group followed by amide reduction with LiAlH4 formed 
intermediates 9a-k. Installation of 9a-k to 6 in the same manner as the preparation of 1a-b gave targets 2a-k.     
2.2 Anti-TB activity 
  The two series 1a-b and 2a-e bearing different kinds of amines to ensure the structure diversity were first 
synthesized (Table 1). They were preliminarily screened for in vitro activity against MTB H37Rv ATCC27395 strain, 
using the Microplate Alamar Blue Assay (MABA). [21] The minimum inhibitory concentration (MIC) is defined as the 
lowest concentration effecting a reduction in fluorescence of >90% relative to the mean of replicate bacterium-only 
controls. The MIC values of the compounds along with PBTZ169, isoniazid (INH), and rifampicin (RFP) for 
comparison were obtained from three independent experiments and presented in µg/mL in Table 1. 
                                    <INSERT TABLE 1 HERE> 
  The data revealed that these two BTZ derivatives 1a-b and 2a-e shown considerable anti-TB activity against this 
strain (MIC < 10 µg/mL), although they were less active than PBTZ169, INH and RFP. Among them, compounds 1a-b 
and 2a displayed better activity (MIC < 1 µg/mL) than other BTZs 2b-e. Removal of the methyl group on 1a didn’t 
influence the potency (1a vs 1b). Decrease or increase the ring size of the piperidine group on 2a resulted in a loss of 
anti-TB activity (2a vs 2b vs 2c). Replacement of the piperidine group with N-methyl piperazine or diethyl amine also 
leaded to a decreased potency (2a vs 2d vs 2e). Specifically, compound 2d shown more than 16-fold higher MIC value 
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than that of 2a. Consequently, this set of modification suggested that the cyclohexylamino (1a-b) and 
piperidin-1-ylmethyl (2a) moiety were more suitable for the Q fragment (Table 1) than other moieties. Considering 
compound 2a displayed best activity (MIC = 0.481 µg/mL) among these two series, we intend to make further 
optimization based on 2a.  
                                  <INSERT TABLE 2 HERE> 
   Next, an additional set of substituted piperidine analogues as W moiety listed in Table 2 were designed and 
synthesized. Our results indicated that some of them (2g-i) exhibited good activity (MIC < 1 µg/mL). Among them, 
compound 2i (MIC < 0.016 µg/mL) is more active than INH (MIC = 0.037 µg/mL) and RFP (MIC = 0.084 µg/mL), 
and comparable to PBTZ169 (MIC < 0.016 µg/mL). Exploration of SAR was first conducted by introduction of methyl 
group to ortho-, meta-, and para-positions of piperazine ring. Introduction of methyl group to ortho-position provided 
decreased potency (2a vs 2f), whereas the presence of meta- or para-methyl group afforded a slightly increased or 
maintained anti-TB activity (2a vs 2g and 2h). The installation of hydroxy or ketal groups at the para-position was 
detrimental to the potency (2a vs 2j and 2k). Surprisingly, the introduction of trifluoro group at the para position caused 
a dramatical improvement in potency (2a vs 2i).        
   Inspired by the strong anti-TB potency against drug sensitive strain, compound 2i was further evaluated against two 
clinical isolated MDR-TB strains (16995 and 16833) resistant to both INH and RFP (MIC > 40 µg/mL). As shown in 
table 3, compound 2i (MIC < 0.016 µg/mL) displayed comparable anti-MDR-TB activity to PBTZ169 (MIC < 0.016 
µg/mL), suggesting its promising potential for both drug-sensitive and resistant TB strains.   
                                  <INSERT TABLE 3 HERE> 
2.3 Pharmacokinetics       
  We subsequently investigated the in vivo PK profiles of compound 2i in mice after a single oral administration of 50 
mg/kg. As shown in Table 4, compound 2i showed acceptable PK properties although the AUC of 2i (2489 h·ng/mL) is 
less than half of PBTZ169 (5478 h·ng/mL). The Tmax of 2i (0.25 h) is shorter than PBTZ169 (0.83 h), indicating that 
2i was absorbed faster than PBTZ169. The Cmax is comparable to PBTZ169. We speculated that the lower AUC of 2i 
probably due to extensive tissue distribution or excretion. Currently, the PK profiles of 2i in lung is under testing, 
which will give the lung distribution properties of 2i.  
                                   <INSERT TABLE 4 HERE> 
3. Conclusion 
   In summary, two series of BTZ derivatives with piperidine ring were designed as new anti-TB agents through 
modifications of IMB-ZR-1. Most of them exhibited considerable in vitro inhibitory (MIC < 10 µg/mL) activity against 
drug sensitive strain. Compound 2i with 4-trifuoromethyl piperidine group as the W moiety of series 2 displayed 
comparable in vitro anti-TB activity to PBTZ169 against drug-sensitive and resistant TB strains. Compound 2i also 
showed acceptable PK profiles, although its AUC is less than half of PBTZ169. Studies to determine further PK 
profiles in lung and in vivo efficacy of 2i are currently under way.   
4. Experimental protocols 
4.1. Chemistry 
   Melting points were determined in open capillaries and are uncorrected. 1H NMR spectra were determined on a 
Varian Mercury-400 spectrometer in DMSO-d6 or CDCl3 using tetramethylsilane as an internal standard. Electrospray 
ionization (ESI) mass spectra was obtained on an MDSSCIEX Q-Tap mass spectrometer. The reagents were all of 
analytical grade or chemically pure. TLC was performed on silica gel plates (Merck, ART5554 60F254). 
4.2. Synthesis 
4.2.1. General procedure for the preparation of compound 4a-b 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
  To a stirred solution of tert-butyl 4-oxopiperidine-1-carboxylate (200 mg, 0.67 mmol) in anhydrous MeOH (5 mL) 
was added N-methylcyclohexanamine/cyclohexanamine, NaCNBH3 (166 mg, 2.68 mmol) at room temperature. The 
mixture was adjusted to pH 6 by acetic acid, and stirred for 3 hours. The mixture quenched by H2O (20 mL), and 
extracted by DCM. The organic layer was dried over anhydrous MgSO4, filtered and concentrated. The residue was 
purified by chromatography on a silica gel column to yield compound 4a-b.  
4.2.1.1. tert-butyl 4-(cyclohexyl(methyl)amino)piperidine-1-carboxylate 4a    
  Following the general procedure, employing N-methylcyclohexanamine yielded compound 4a as a colorless oil in 
40% yield, 1HNMR (500 MHz, CDCl3) δ 4.30 (2H, brs), 3.34 (1H, brs), 3.17 (1H, brs), 2.73 (2H, brs), 2.65 (3H, s), 
2.20 (2H, m), 1.96 (2H, m), 1.73 (2H, m), 1.58 (2H, brs), 1.42 (9H, s), 1.25 (7H, brs); MS-ESI (m/z): 319 (M + Na)+. 
4.2.1.2. tert-butyl 4-(cyclohexylamino)piperidine-1-carboxylate 4b 
   Following the general procedure, employing cyclohexanamine yielded compound 4b as a colorless oil in 50% yield, 
MS-ESI (m/z): 283 (M + H)+. 
4.2.2. General procedure for the procedure of compound 5a-b 
   To a stirred solution of 4a-b (0.25 mmol) in DCM (5 mL) was added TFA, stirred for 1 hour, and concentrated. The 
residue was diluted by DCM, concentrated again for three times to gave the crude 5a-b which was used directly for the 
next step.   
4.2.3 General procedure for the preparation of compound 8a-k 
  To a stirred solution of compound 7 (200 mg, 0.87 mmol) in DCM (10 mL) was added amines (1.0 mmol), EDC 
(186 mg, 1.2 mmol), and HOBt (153 mg, 1.2 mmol) at room temperature. The mixture was stirred for 3 hrs, quenched 
by H2O (15 mL), and extracted by DCM (15 mL × 3). The organic layer was dried over anhydrous MgSO4, filtered, 
and concentrated. The residue was purified by chromatography on a silica gel column to afford compound 8a-l as a 
colorless oil.     
4.2.3.1.   tert-butyl 4-(piperidine-1-carbonyl)piperidine-1-carboxylate 8a 
   Following the general procedure, employing piperidine as the amine yielded compound 8a as a colorless oil in 85% 
yield, 1H NMR (500 MHz, CDCl3) δ 4.14 (brs, 2H), 3.55 (brs,2H), 3.43 (brs, 2H), 2.76 (brs, 2H), 2.62 (m, 1H), 1.66 (m, 
6H), 1.55 (brs, 4H), 1.45 (s, 9H); MS-ESI (m/z): 297 (M + H)+. 
4.2.3.2. tert-butyl 4-(pyrrolidine-1-carbonyl)piperidine-1-carboxylate 8b 
   Following the general procedure, employing piperidine as the amine yielded compound 8b as a colorless oil in 90% 
yield, which was used directly for the next step. 
4.2.3.3. tert-butyl 4-(azepane-1-carbonyl)piperidine-1-carboxylate 8c 
   Following the general procedure, employing azepane as the amine yielded compound 8c as a colorless oil in 94% 
yield, 1H NMR (500 MHz, CDCl3) δ 4.15(brs, 2H), 3.51(brs,2H), 3.47(t, J = 5.9 Hz, 2H), 2.75(brs, 2H), 2.60(m, 1H), 
2.01(m, 2H), 1.73(m, 6H), 1.57(brs, 4H), 1.46(s, 9H); MS-ESI (m/z): 333 (M + Na)+. 
4.2.3.4. tert-butyl 4-(4-methylpiperazine-1-carbonyl)piperidine-1-carboxylate 8d    
    Following the general procedure, employing azepane as the amine yielded compound 8d as a colorless oil in 75% 
yield, 1H NMR (500 MHz, CDCl3) δ 4.14 (brs, 2H), 3.65 (brs, 2H), 3.53 (brs, 2H), 2.75 (brs, 2H), 2.6 1(m, 1H), 2.41 (d, 
J = 13.4 Hz, 4H), 2.32 (s, 3H), 1.67 (m, 4H), 1.45 (s, 9H); MS-ESI (m/z): 312 (M + H)+, 334 (M + Na)+. 
4.2.3.5. tert-butyl 4-(diethylcarbamoyl)piperidine-1-carboxylate 8e 
    Following the general procedure, employing diethylamine as the amine yielded compound 8e as a colorless oil in 
80% yield, 1H NMR (500 MHz, CDCl3) δ 4.15 (brs, 2H), 3.34 (q, J = 9.3 Hz, 4H), 2.74 (brs, 2H), 2.54 (t, J = 11.0 HZ, 
1H), 1.75 (q, J = 10.1 Hz, 2H), 1.6 3(m, 2H), 1.45 (s, 9H), 1.20 (t, J = 6.9 HZ, 3H), 1.09 (t, J = 6.9 HZ, 3H); MS-ESI 
(m/z): (M + H)+; MS-ESI (m/z): 285 (M + H)+. 
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4.2.3.6. tert-butyl 4-(2-methylpiperidine-1-carbonyl)piperidine-1-carboxylate 8f 
   Following the general procedure, employing 2-methylpiperidine as the amine yielded compound 8f as a colorless 
oil in 87% yield, 1H NMR (500 MHz, CDCl3) δ 4.92 (brs, 1H), 4.49 (m, 1H), 4.15 (brs, 3H), 3.66 (m, 1H), 3.13 (m, 
1H), 2.76 (brs, 2H), 2.59 (brs, 1H), 1.63 (m, 8H), 1.45 (s, 9H), 1.27 (brs, 3H); MS-ESI (m/z): 333 (M + Na)+. 
4.2.3.7. tert-butyl 4-(3-methylpiperidine-1-carbonyl)piperidine-1-carboxylate 8g    
    Following the general procedure, employing 3-methylpiperidine as the amine yielded compound 8g as a colorless 
oil in 87% yield, 1H NMR (500 MHz, CDCl3)δ4.43 (m, 1H), 4.14 (brs, 2H), 3.80 (d, J = 11.8 Hz, 1H), 3.71 (d, J = 13.4 
Hz, 1H), 2.98 (m, 1H), 2.76 (brs, 2H), 2.63 (m, 1H), 2.24 (t, J = 11.2 Hz, 1H), 1.83 (d, J=12.5 Hz, 1H), 1.68 (m, 5H), 
1.45 (brs, 9H), 1.25 (m, 1H), 1.15 (m, 1H), 0.92 (d, J = 10.7 Hz, 3H); MS-ESI (m/z): 333 (M + Na)+. 
4.2.3.8. tert-butyl 4-(4-methylpiperidine-1-carbonyl)piperidine-1-carboxylate 8h    
    Following the general procedure, employing 4-methylpiperidine as the amine yielded compound 8h as a colorless 
oil in 87% yield,
 1H NMR (500 MHz, CDCl3) δ 4.57 (brs, 1H), 4.14 (brs, 2H), 3.85 (brs, 1H), 3.01 (brs, 1H), 2.76 (m, 
2H), 2.62 (m, 1H), 2.54 (m, 1H), 1.66 (m, 7H), 1.45 (s, 9H), 1.08 (m, 2H), 0.95 (d, J = 6.5 Hz, 2H). 
4.2.3.9. tert-butyl 4-(4-(trifluoromethyl)piperidine-1-carbonyl)piperidine-1-carboxylate 8i 
    Following the general procedure, employing 4-trifluoromethylpiperidine as the amine yielded compound 8i as a 
colorless oil in 68% yield, 1H NMR (500 MHz, CDCl3) δ 4.75 (d, J = 11.2 Hz, 1H), 4.14 (brs, 2H), 4.01 (d, J = 11.4 Hz, 
1H), 3.05 (m, 1H), 2.77 (brs, 2H), 2.61 (m, 1H), 2.53 (m, 1H), 2.28 (m, 1H), 1.94 (m, 2H), 1.72 (m, 2H), 1.66 (brs, 2H), 
1.45 (brs, 11H); MS-ESI (m/z): 365 (M + H)+. 
4.2.3.10. tert-butyl 4-(4-hydroxypiperidine-1-carbonyl)piperidine-1-carboxylate 8j    
    Following the general procedure, employing 4- hydroxypiperidine as the amine yielded compound 8j as a 
colorless oil in 68% yield, 1H NMR (500 MHz, CDCl3) δ 4.08 (m, 2H), 3.95 (brs,2H), 3.76 (brs, 1H), 3.23 (m, 2H), 
2.76 (brs, 2H), 2.63 (brs, 1H), 2.07 (m, 2H), 1.89 (brs, 2H), 1.69 (brs, 2H), 1.50 (m, 2H), 1.45 (brs, 9H); MS-ESI (m/z): 
335 (M + Na)+. 
4.2.3.11. tert-butyl 4-(1,4-dioxa-8-azaspiro[4.5]decane-8-carbonyl)piperidine-1-carboxylate 8k 
   Following the general procedure, employing 4- hydroxypiperidine as the amine yielded compound 8k as a colorless 
oil in 75% yield, 1H NMR (500 MHz, CDCl3) δ 4.14 (d, J = 11.6 Hz, 2H), 3.98 (s, 4H), 3.68 (brs, 2H), 3.56 (brs, 2H), 
2.76 (t, J = 12.2 Hz, 2H), 2.64 (m, 1H), 1.69 (m, 8H), 1.45 (s, 9H); MS-ESI (m/z): 355 (M + H)+. 
4.2.4. General procedure for the preparation of 9a-k 
   To a stirred solution of 8a-k (0.25 mmol) in DCM (5 mL) was added TFA, and stirred for 1 hour. The mixture was 
concentrated, and diluted by DCM, concentrated again for three times to fully remove the TFA. The residue was 
dissolved in THF. To the mixture was added LiAlH4 (0.5 mL,1 M solution in THF) at 0 oC, and stirred for 30 mins. The 
mixture was slowly quenched by MeOH (0.5 mL), and NaOH solution (0.2 mL, 1 M). The mixture was filtered through 
celite, washed by MeOH, and concentrated. The residue was concentrated and purified by chromatography on a silica 
gel column (DCM : MeOH : NH3·H2O = 5 : 3 : 1) to afford crude 9a-k as brown oils，which were used directly for the 
next step. 
4.2.5. General procedure for the preparation of 1a-b and 2a-k     
   To a stirred solution of 5a-b or 9a-k (0.1 mmol) in anhydrous MeOH (5 mL) was added compound 6 (32 mg, 0.1 
mmol) and Et3N (28 µL, 0.2 mmol) at room temperature under argon. The mixture was heated to 40 oC, stirred for 3 
hours, and concentrated. The mixture was diluted by DCM (15 mL) and washed by H2O. The organic layer was dried 
over anhydrous MgSO4, filtered, and concentrated. The residue was purified by chromatography on a silica gel column 
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(DCM : MeOH : NH3·H2O = 10 : 1 : 0.01) or prepare TLC (DCM : MeOH : NH3·H2O = 10 : 1 : 0.01) to give BTZs 
1a-b or 2a-k.  
4.2.5.1. 2-(4-(cyclohexyl(methyl)amino)piperidin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one 1a 
   Following the general procedure, employing 5a yielded compound 1a as yellow solid in 40% yield, mp:146-148 oC; 
HPLC purity, 98.1%; 1H NMR (500 MHz, CDCl3) δ 9.09 (1H, s), 8.75 (1H, s), 5.24 (1H, brs), 4.43 (1H, brs), 3.18 
(2H,brs), 3.05 (1H, brs), 2.68 (1H,brs), 2.35 (3H, s), 2.05 (2H, brs), 1.83 (4H, brs), 1.65 (2H, d, J = 11.7 Hz), 1.37 (2H, 
m), 1.26 (2H, m), 1.12 (2H, m); ESI-MS (m/z): 471 (M + H)+. 
4.2.5.2. 2-(4-(cyclohexylamino)piperidin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one 1b 
   Following the general procedure, employing 5b yielded compound 1b as yellow solid in 40% yield, mp:171-173 oC; 
HPLC purity, 96.3%; 1H NMR (500 MHz, CDCl3) δ 9.09 (1H, s), 8.75 (1H, s), 4.99 (1H, brs), 4.34 (1H, brs), 3.48 (1H, 
s), 3.38 (2H, brs), 3.11 (1H, brs), 2.62 (1H, brs), 2.09 (2H, brs), 1.91 (2H, d, J = 9.65 Hz), 1.76 (2H, d, J = 12.3 Hz), 
1.63 (2H, d, J = 11.8 Hz), 1.53 (2H, brs), 1.26 (2H, m), 1.16 (2H, m); ESI-MS (m/z): 457 (M + H)+. 
4.2.5.3. 8-nitro-2-(4-(piperidin-1-ylmethyl)piperidin-1-yl)-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one 2a 
   Following the general procedure, employing 9a yielded compound 2a as yellow solid in 40% yield, mp:165-167 oC; 
HPLC purity, 99.0%; 1H NMR (500 MHz, CDCl3) δ (ppm) 9.10 (s, 1H), 8.74 (s, 1H), 5.25 (brs, 1H), 4.37 (brs, 1H), 
3.29 (brs, 1H), 3.01 (brs, 1H), 2.35 (brs, 4H), 2.18-1.95 (m, 7H), 1.57-1.27 (m, 6H); 13C NMR (400 MHz, CDCl3) δ 
(ppm) 166.46, 161.62, 144.03, 134.28, 133.26 (q, J = 3.5 Hz), 129.61 (q, J = 35.4 Hz), 126.88, 125.85 (q, J = 3.6 Hz), 
122.44 (q, J = 272.95 Hz), 64.36, 55.20, 46.94, 33.63, 30.84, 25.63, 24.16; ESI-MS (m/z): 457 (M + H)+. 
4.2.5.4. 8-nitro-2-(4-(pyrrolidin-1-ylmethyl)piperidin-1-yl)-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one 2b 
   Following the general procedure, employing 9b yielded compound 2b as yellow solid in 20% yield, mp:156-158 oC; 
HPLC purity, 93.9%; 1H NMR (500 MHz, CDCl3) δ (ppm) 9.09 (s, 1H), 8.74 (s, 1H), 5.30-5.24 (m, 1H), 4.38 (brs, 1H), 
3.91-3.05 (m, 2H), 2.71 (brs, 4H), 2.52 (brs, 3H), 2.21-2.00 (m, 4H), 1.87 (brs, 2H), 1.35-1.25 (m, 2H); 13C NMR (400 
MHz, CDCl3) δ (ppm) 166.57, 161.74, 143.94, 134.30, 133.34 (q, J = 3.4 Hz), 129.60(q, J = 35.4 Hz), 126.73, 126.00 
(q, J = 3.7 Hz), 122.42(q, J = 273.5 Hz), 61.72, 54.76, 46.81, 35.08, 30.67, 23.48; ESI-MS (m/z): 443 (M + H)+. 
4.2.5.5. 2-(4-(azepan-1-ylmethyl)piperidin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one 2c 
   Following the general procedure, employing 9c yielded compound 2c as yellow solid in 28% yield, mp: 141-143 oC; 
HPLC purity, 92.8%; 1H NMR (500 MHz, CDCl3) δ (ppm) 9.10 (s, 1H), 8.74 (s, 1H), 5.30-5.24 (m, 1H), 4.38 (brs, 1H), 
3.29 (brs, 1H), 3.04 (brs, 1H), 2.67 (brs, 4H), 2.40 (brs, 2H), 2.22-1.88 (m, 5H), 1.62 (d, J = 26.0 Hz, 6H), 1.28-1.25 (m, 
2H); 13C NMR (400 MHz, CDCl3) δ (ppm) 166.61, 161.62, 143.95, 134.39, 133.34(q, J = 35.3 Hz), 126.78, 125.97 (q, 
J = 3.6 Hz), 122.44 (q, J = 272.4 Hz), 63.29, 55.98, 47.16, 34.81, 30.75, 27.83, 27.17; ESI-MS (m/z): 471.6 (M + H)+.  
4.2.5.6. 2-(4-((4-methylpiperazin-1-yl)methyl)piperidin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3] 
thiazin-4-one 2d 
   Following the general procedure, employing 9d yielded compound 2d as yellow solid in 28% yield, mp: 143-145 oC; 
HPLC purity, 95.1%; 1H NMR (500 MHz, CDCl3) δ (ppm) 9.09 (s, 1H), 8.74 (s, 1H), 5.25 (brs, 1H), 4.37 (brs, 1H), 
3.28-3.20 (m, 1H), 3.11-3.00 (m, 1H), 2.53 (brs, 8H), 2.37 (s,3H), 2.24 (d, J = 6.6Hz, 2H), 1.99-1.90 (m, 3H), 1.28-1.26 
(m, 2H); 13C NMR (400 MHz, CDCl3) δ (ppm) 166.57, 161.67, 143.95, 134.32, 133.35 (q, J = 3.5 Hz), 129.59 (q, J = 
35.5 Hz), 126.76, 125.98 (q, J = 3.6 Hz), 122.42 (q, J = 271.6 Hz), 63.53, 54.90, 52.96, 46.96, 45.58, 33.60, 30.67; 
ESI-MS (m/z): 472.6 (M + H)+. 
4.2.5.7. 2-(4-((diethylamino)methyl)piperidin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3]thiazin-4-one 2e 
    Following the general procedure, employing 9e yielded compound 2e as yellow solid in 38% yield, mp: 117-118 
oC; HPLC purity, 92.9%; 1H NMR (500 MHz, CDCl3) δ (ppm) 9.07 (s, 1H), 8.72 (s, 1H), 5.28 (brs, 1H), 4.36 (brs, 1H), 
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3.28 (brs, 1H), 3.06-2.99 (m, 1H), 2.51 (q, J = 7.0 Hz, 4H), 2.27 (d, J = 6.5 Hz, 2H), 2.02-1.99 (m, 2H), 1.86-1.81 (m, 
1H), 1.30-1.21 (m, 2H), 0.99 (t, 6H); ESI-MS (m/z): 445 (M + H)+. 
4.2.5.8. 2-(4-((2-methylpiperidin-1-yl)methyl)piperidin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3] 
thiazin-4-one 2f 
     Following the general procedure, employing 9e yielded compound 2e as yellow solid in 36% yield, mp: 128-130 
oC; HPLC purity, 98.1%; 1H NMR (500 MHz, CDCl3) δ (ppm) 9.09 (s, 1H), 8.74 (s, 1H), 5.29-5.25 (m, 1H), 4.37 (brs, 
1H), 3.29 (brs, 1H), 3.00 (brs, 1H), 2.84 (brs, 1H), 2.54 (brs, 1H), 2.62-1.89 (m, 4H), 1.63 (brs,4H), 1.28-1.25 (m, 6H), 
1.02 (s, 3H); 13C NMR (400 MHz, CDCl3) δ (ppm) 166.58, 161.57, 143.39, 133.34(q, J = 3.5 Hz), 129.54 (q, J = 35.2 
Hz), 126.79, 125.96 (q, J = 3.7 Hz), 122.44 (q, J = 272.9 Hz), 59.31, 56.88, 53.12, 47.19, 34.71, 30.90, 25.93, 23.57, 
19.05, 14.15; ESI-MS (m/z): 471 (M + H)+. 
4.2.5.9.  2-(4-((3-methylpiperidin-1-yl)methyl)piperidin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3] 
thiazin-4-one 2g 
     Following the general procedure, employing 9g yielded compound 2g as yellow solid in 36% yield, mp: 127-128 
oC; HPLC purity, 98.1%; 1H NMR (500 MHz, CDCl3) δ (ppm) 9.10 (s, 1H), 8.74 (s, 1H), 5.34-5.25 (m, 1H), 4.37 (brs, 
1H), 3.30 (brs, 1H), 3.02 (brs, 1H), 2.72 (brs, 2H), 2.16 (brs, 2H), 2.04-1.85 (m, 5H), 1.70-1.55 (m, 5H), 1.26 (brs, 2H), 
0.86 (d, J = 5.7 Hz, 3H); 13C NMR (400 MHz, CDCl3) δ (ppm) 166.60, 161.62, 143.95, 134.39, 133.34(q, J = 3.4 Hz), 
129.56(q, J = 35.5 Hz), 126.79, 125.96 (q, J = 3.7 Hz), 122.44 (q, J = 273.8 Hz), 64.36, 62.79, 54.78, 47.12, 33.81, 
32.98, 31.09, 29.35, 25.51, 19.71; ESI-MS (m/z): 471 (M + H)+. 
4.2.5.10. 2-(4-((4-methylpiperidin-1-yl)methyl)piperidin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3] 
thiazin-4-one 2h 
     Following the general procedure, employing 9h yielded compound 2h as yellow solid in 36% yield, mp: 130-131 
oC; HPLC purity, 97.6%; 1H NMR (500 MHz, CDCl3) δ (ppm) 9.14 (s, 1H), 8.79 (s, 1H), 5.39-5.28 (m, 1H), 4.41 (brs, 
1H), 3.33 (brs, 1H), 3.06 (brs, 1H), 2.84 (brs, 1H), 2.22 (d, J = 4.0 Hz, 2H), 1.96 (brs, 5H), 1.66-1.63 (m, 3H), 1.30 (brs, 
4H), 0.97 (d, J = 6.3 Hz, 3H); 13C NMR (400 MHz, CDCl3) δ (ppm) 166.58, 161.62, 143.94, 133.33 (q, J = 3.5 Hz), 
129.54 (q, J = 35.4 Hz), 126.79, 125.95(q, J = 3.6 Hz), 122.44(q, J = 273.2 Hz), 63.21, 54.65, 53.46, 47.06, 34.27, 
33.84, 30.78, 21.87; ESI-MS (m/z): 471 (M + H)+. 
4.2.5.11. 8-nitro-6-(trifluoromethyl)-2-(4-((4-(trifluoromethyl)piperidin-1-yl)methyl)piperidin-1-yl)-4H-benzo[e][1,3] 
thiazin-4-one 2i 
     Following the general procedure, employing 9i yielded compound 2i as yellow solid in 36% yield, mp: 
158-159 oC; HPLC purity, 98.4%; 1H NMR (500 MHz, CDCl3) δ (ppm) 9.14 (s, 1H),8.79 (s, 1H),5.30 (brs, 1H), 4.43 
(brs, 1H), 3.33 (brs, 1H), 2.98 (brs, 4H), 2.26 (brs, 2H), 2.01 (brs, 3H), 1.87 (brs, 4H), 1.66 (brs,2H), 1.32 (d, J = 7.2 Hz, 
2H); 13C NMR (400 MHz, CDCl3) δ (ppm) 166.58, 161.70, 143.95, 134.30, 133.35 (q, J = 3.5 Hz), 129.61 (q, J = 35.5 
Hz), 126.75, 126.00 (q, J = 3.6 Hz), 122.42 (q, J = 272.5 Hz),63.73, 53.08, 46.92, 40.33 (q, J = 28.4 Hz), 33.83, 30.69, 
24.63; ESI-MS (m/z): 525.6 (M + H)+. 
4.2.5.12. 2-(4-((4-hydroxypiperidin-1-yl)methyl)piperidin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e][1,3] 
thiazin-4-one 2j 
   Following the general procedure, employing 9j yielded compound 2j as yellow solid in 36% yield, mp: 78-80 oC; 
HPLC purity, 93.4%; 1H NMR (500 MHz, CDCl3)δ(ppm) 9.09(s, 1H),8.7 5(s, 1H), 5.26 (brs, 1H), 4.39 (brs, 1H), 
3.71-3.52 (m, 1H), 3.29-3.04 (m, 5H), 2.73 (brs, 2H), 2.33-2.20 (m, 4H), 2.00-1.90 (m, 3H), 1.56 (brs, 2H), 1.26 (brs, 
2H); 13C NMR (400 MHz, CDCl3) δ (ppm) 166.60, 161.71, 143.95, 134.32, 133.36 (q, J = 3.3 Hz), 129.60 (q, J = 34.9 
Hz), 126.75, 126.00 (q, J = 3.3 Hz), 122.42 (q, J = 273.1 Hz), 63.51, 51.60, 46.98, 34.47, 33.91, 30.79, 29.72, 29.35, 
27.24; ESI-MS (m/z): 473.6 (M + H)+. 
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4.2.5.13. 2-(4-((1,4-dioxa-8-azaspiro[4.5]decan-8-yl)methyl)piperidin-1-yl)-8-nitro-6-(trifluoromethyl)-4H-benzo[e] 
[1,3]thiazin-4-one 2k 
    Following the general procedure, employing 9k yielded compound 2k as yellow solid in 36% yield, mp: 78-80 oC; 
1H NMR (500 MHz, CDCl3) δ 9.09 (s, 1H), 8.75 (s, 1H), 5.34-5.25 (m, 1H), 4.41 (brs, 1H), 3.96 (brs, 4H), 3.28 (brs, 
1H), 3.05 (brs, 1H), 2.59 (brs, 4H), 2.40-2.33 (m, 2H), 2.23-2.20 (m, 1H), 1.79-1.77 (brs, 4H), 1.63-1.58 (m, 2H), 1.27 
(brs, 2H); 13C NMR (400 MHz, CDCl3) δ (ppm) 166.58, 161.72, 143.95, 134.30, 133.36 (q, J = 3.6 Hz), 129.60 (q, J =3 
5.9 Hz), 126.75, 126.00(q, J = 3.6 Hz), , 122.42 (q, J = 272.9 Hz), 64.37, 63.13, 51.99, 46.78,34.48, 33.80, 30.84, 27.24; 
ESI-MS (m/z): 515.6 (M + H)+. 
4.3. MIC determination 
    MICs against replicating M. tuberculosis were determined by the microplate Alamar blue assay (MABA). RIF and 
INH were included as positive controls. M. tuberculosis H37Rv and clinical isolate strains was grown to late log phase 
(70 to 100 Klett units) in Difco Middlebrook 7H9 Broth (catalog no. 271310) supplemented with 0.2% (vol/vol) 
glycerol, 0.05% Tween 80, and 10% (vol/vol) albumin-dextrosecatalase (BBL Middlebrook ADC Enrichment, catalog 
no. 212352) (7H9-ADCTG). Cultures were centrifuged, washed twice, and then suspended in phosphate 
phosphate-buffered saline. Suspensions were then passed through an 8 µm-pore-size filter to remove clumps, and 
aliquots were frozen at -80 °C. Two fold dilutions of target compounds were prepared in 7H9-ADC-TG in a volume of 
100 µl in 96-well, black, clear-bottom microplates (BD Biosciences, Franklin Lakes, NJ). M. tuberculosis (100 µl 
containing 2 × 105 CFU) was added, yielding a final testing volume of 200 µl. The plates were incubated at 37°C; on 
day 7 of incubation, 12.5 µl of 20% Tween 80 and 20 µl of Alamar blue were added to all wells. After incubation at 
37 °C for 16 to 24 h, the fluorescence was read at an excitation of 530 nm and an emission of 590 nm. The MIC was 
defined as the lowest concentration effecting a reduction in fluorescence of ≥90% relative to the mean of replicate 
bacterium-only controls.  
4.4. Pharmacokinetic Profiles determination   
   SPF female ICR mice weighing 20-25 g were used in the pharmacokinetic study. The rats were fasted overnight 
before dosing. Every treatment group contained 3 mice. Mice were dosed with the tested compounds suspension at 
50 mg/kg (p.o.). Compounds were suspended in 0.5% CMC for oral administration. Blood was collected from the 
jugular vein of each animal at the following times after administration of drugs: 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h after a 
single oral dosing. All blood samples were centrifuged at 3000 r/min for 10 min to obtain serum which was then stored 
at −20 °C. 150 µL of the serum was added to 500 µL of acetonitrile and the mixture was centrifuged at 13000 r/min for 
10 min to remove protein. The supernatant was dried and dissolved in 100 µL of acetonitrile, the solution was 
centrifuged at 13000 r/min for 10 min. The supernatant was moved to a sample bottle for HPLC analysis. Total area 
under the concentration time curve (AUC), the elimination half-time (t1/2), the peak concentration (Cmax) and the time to 
reach peak concentration (Tmax) of samples were determined directly from the experimental data using WinNonlin 
V6.2.1. 
4.5 HPLC purity determination.  
   All samples were performed on an Agilent 1260 HPLC-UV system. Conditions (solvent A = methanol, solvent B = 
0.1% TFA + H2O): Zorbax SB-C18 column (250 mm × 4.6 mm, 5 µm, PN: 883975-902). Injection volumn: 10 µL. 
Flow: 1.3 mL/min. Gradient elution: 0.00 min, 10% A; 3 min, 50% A; 15 min, 100% A; 16 min, 10% A; 18 min 10%A. 
UV at 254 nm.  
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TB, tuberculosis; MTB, Mycobacterium tuberculosis; MDR, multidrug-resistant; XDR, extensively drug-resistant; 
WHO, World Health Organization; ATP, adenosine triphosphate; hERG, human ether-a-go-go related gene; ADME, 
absorption, distribution, metabolism, excretion, toxicity; BTZs, nitrobenzothiazinones; DprE1, Decaprenyl 
phosphoryl-β-D-ribose 2/-epimerase; SAR, structure-activity relationship; PK, pharmacokinetic; MeOH, methanol; 
NaCNBH3, sodium cyanoborohydride; TFA, trifluoroacetic acid; DCM, methylene chloride; MIC, minimum inhibitory 
concentration; HOBt, hydroxybenzotriazole; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; LiAlH4, lithium 
aluminum hydride; MABA, microplate alamar blue assay; INH, isoniazid; RFP, rifampicin; T1/2,  half-life; Cmax, the 
maximum serum concentration; Tmax, the time at which the Cmax is observed; AUC, area under the curve;  MRT, 
mean residence time. 
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Table 1. Structures and activities of 1a-b and 2a-e  
N
S N
O
NO2
F3C
Q
 
Compd. Q MIC 
1a 
 
0.973 
1b 
 
0.959 
2a 
 
0.481 
2b 
 
3.578 
2c N
 
1.320 
2d N
N
Me
 
7.844 
2e 
 
1.825 
PBTZ169  <0.016 
INH  0.037 
RFP  0.084 
                                 
                                 INH: isoniazid; RFP: rifampicin 
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Table 2. Structures and activities of 1a-b and 2a-e 
 
Compd. W MIC 
2a 
 
0.481 
2f 
 
1.922 
2g 
 
0.241 
2h 
 
0.488 
2i 
 
<0.016 
2j 
 
1.961 
2k 
 
3.709 
PBTZ169  <0.016 
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Table 3. Anti-MDR TB activity of compound 2i 
Compd. 
MIC (µg/mL) 
MDR-TB 16995a MDR-TB 16883a 
2i <0.016 <0.016 
PBTZ169 <0.016 <0.016 
INH >40 >40 
RFP >40 >40 
INH: isoniazid; RFP: rifampicin; a MDR-TB 16995 and MDR-TB 16883 were isolated from patients in Beijing Chest Hospital.  
 
 
 
 
Table 4. PK profiles of compound 2i dosed orally in mice at 50 mg/kg (n = 3) 
PK parameters 2i PBTZ169 
T1/2 (h) 3.3 ± 3.01 2.87 ± 1.03 
Tmax (h) 0.25 ± 0 0.83 ± 0.29 
Cmax (ng/mL) 1165 ± 223 1300 ± 422 
AUC0-inf (h·ng/mL) 2489 ± 1273 5478 ± 1730 
MRT (h) 4.26 ± 3.74 3.73 ± 0.94 
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Figure 1. Design of new BTZs 
 
 
 
 
 
 
Scheme 1. Synthesis of BTZs 1a-b and 2a-k 
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Highlights: 
1. Two series of BTZs 1-2 with piperidine moiety were designed and synthesized.  
2. Some targets showed considerable in vitro activity (MIC<1 µg/mL) against MTB strain. 
3. Compound 2i displayed potent in vitro anti-MDR-TB activity (MIC < 0.016 µg/mL). 
 
